Purpose: Epidermal growth factor receptor (EGFR) gene copy number obtained by fluorescence in situ hybridization (FISH) has been recently found to predict treatment outcome in non-small cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. However, it is still unknown whether EGFR status differs in metastases compared with primary NSCLC. In all studies FISH have been performed on histologic material. The possibility to perform FISH analysis on cytologic material obtained by fine-needle aspiration from superficial and visceral metastases would allow us to know the real EGFR status avoiding invasive diagnostic procedures. Methods: EGFR gene copy number was analyzed by FISH on fine-needle aspirates obtained from 31 patients with metastatic NSCLC and the results were compared with those obtained on corresponding paraffin histologic sections from the primary tumor. Results: The feasibility of EGFR FISH on cytology was 90% (28 of 31 patients). EGFR FISH was positive in 61% (17 of 28 patients) of the metastases and in 36% (10 of 28 patients) of the primary tumors. Nine of the 28 cases (32%) were EGFR positive on both primary tumor and metastatic site and 10 (36%) were negative on both primary tumor and metastasis. Nine of the 28 cases (32%) showed discordance of primary tumor versus metastasis (McNemar test; p ϭ 0.041). Conclusions: EGFR FISH can be reliably assessed on fine-needle aspirates obtained from NSCLC metastases. We found that EGFR gene copy number is discordant between primary NSCLC and the corresponding distant metastatic sites in a significant proportion of cases. These findings should be considered in future studies designed to elucidate the predictive role of EGFR FISH in NSCLC.
A pproximately one third of all cancer-related deaths in Western countries are because of lung cancer. Non-small cell lung cancer (NSCLC) represents 75 to 80% of lung cancer cases and accounts for approximately 1.2 million new cases worldwide each year. 1 The current standard of care for patients with advanced NSCLC is systemic chemotherapy. However, this treatment does not result in cure and nearly all patients succumb to their disease. 2 During the last few years, significant advances in the development of new molecularly targeted agents have been made. One example of such targets is the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor overexpressed in many human epithelial malignancies, including NSCLC. After stimulation by its natural ligands, this receptor initiates signal transduction cascades that promote cell division, migration, angiogenesis, and inhibit apoptosis. 3 Gefitinib and erlotinib, small molecules that reversibly target EGFR, represent a new reality in the treatment of NSCLC, although only a limited percentage of patients seem to benefit from such agents. Patients with higher probability of response seem to be those of female sex, never smokers, of Asian ethnicity, with histology of adenocarcinoma (ADK) and, particularly, with ADK with bronchioloalveolar-like growth pattern. 4 The discovery that specific EGFR gene mutations in the tyrosine kinase domain (in exons 18 -21) account for increased sensitivity to gefitinib or erlotinib has opened a new avenue for NSCLC patient selection. 5 Recent studies have suggested that EGFR gene copy number assessed by fluorescence in situ hybridization (FISH) or EGFR immunohistochemistry (IHC) could be used to predict which patients will respond to EGFR tyrosine kinase inhibitors (TKIs). 6 One potential limitation of these studies, however, was their reliance on surgical specimens to obtain sufficient ma-terial for immunohistochemical, mutational, and FISH analyses. Unfortunately, many NSCLC cases present at diagnosis in advanced stage when operation is not recommended. In these cases, the samples available for analysis are typically of low volume such as fine-needle aspirate (FNA) cytologic material, obtained as diagnostic procedure. Therefore, in the clinical practice the diagnosis of most patients is made on cytology. Therefore it seems extremely important to test the feasibility and reliability of EGFR status on NSCLC cytologic specimens. In a previous study, we demonstrated the feasibility and reliability of HER-2/neu FISH characterization in cytologic samples from breast distant metastases. 7 Besides, it is still unknown whether EGFR biology differs in metastases compared with primary NSCLC.
The aim of the current study was to evaluate the feasibility of EGFR assessment by FISH on cytologic samples from distant NSCLC metastases and to compare the results with those obtained by FISH on histologic sections from the primary tumor.
MATERIALS AND METHODS
The current series included cytologic specimens obtained by FNA, for diagnostic purpose, from 31 patients with advanced NSCLC who presented with metastatic lesions localized to liver (n ϭ 2), pleura (n ϭ 2), abdomen (n ϭ 1), ribs (n ϭ 2), skin (n ϭ 4), and superficial lymphnodes (n ϭ 20).
Cytologic smears from each metastatic site were partly submitted to May-Grünwald-Giemsa (MGG) staining for routine cytologic diagnosis and partly to FISH for EGFR evaluation. In addition, EGFR FISH was assessed on paraffinembedded histologic sections obtained from corresponding primary NSCLCs. Histologic specimens of primary tumors of these patients were obtained from transbronchial biopsy in 14 cases and from operation in 17 cases, respectively. This study was approved by the institutional ethical review board and written informed consent was obtained from each patient before enrollment.
EGFR FISH on Cytologic Smears Sample Collection
Cytologic smears from superficial palpable metastatic lesions (lymphnodes, skin, and ribs) were obtained by fineneedle aspiration biopsy (FNAB) using a 22-gauge needle and a 20-ml syringe, whereas nonpalpable metastases (liver and abdomen) were sampled by ultrasound-guided FNAB. The aspirated material obtained by FNAB from superficial or deep metastatic lesions was smeared on glass slides and air dried. Cellular suspensions obtained from pleural fluids were cyto-centrifuged and partly air dried. At least two slides were stained with MGG for routine cytology. The remaining slides were kept unstained at room temperature until the assay. After cytologic diagnosis of malignancy, one representative slide was submitted to EGFR FISH.
Pretreatment of Cytologic Slides
Unstained slides were fixed in absolute methanol, air dried, incubated in wash buffer (0.3% NP-40, 2ϫ salinesodium citrate buffer [pH 7.0 -7.5]) at 37°C for 30 minutes, dehydrated through gradients of 70, 85, and 100% ethanol, air dried, and processed by FISH. Archival cytologic slides, stained with MGG, were treated with xylene to remove the coverslip and rinsed twice for 10 minutes each in clean xylene. After washing three times for 10 minutes each in Carnoy solution, the slides were dehydrated gradually in ethanol and processed by FISH. An alternative pretreatment with proteinase K was required for destained smears demonstrating considerable thickness. In this case, destained slides were dehydrated through an ethanol gradient and incubated for 5 minutes at 37°C in 20 g/ml proteinase K. After washing in water and ethanol dehydration, the slides were air dried before being evaluated by FISH.
Fluorescence in Situ Hybridization
After pretreatment, FISH assays were performed using the LSI EGFR Spectrum Orange/CEP 7 Spectrum Green probe (Vysis, Downers Grove, IL). Samples were denatured at 67°C for 5 minutes and hybridized overnight at 37°C in a HY-Brite denaturation/hybridization system for FISH (Vysis). The following day, slides were incubated in wash buffer at 72°C for 2 minutes, air dried in the dark, and counterstained with 4,6-diamidino-2-phenylindole (DAPI). A positive control slide was included in each run. Slides were viewed at a magnification of ϫ1250 on an Olympus CX40 fluorescence microscope (Olympus, Inc., Melville, NY) using a triple excitation/emission filter for simultaneous detection of Spectrum Orange, Spectrum Green, and DAPI. At least 100 assessable nuclei for each case were scored visually. Samples were classified as FISH positive both when at least four copies of EGFR gene were found in more than 40% of cells and in the presence of gene amplification (defined by presence of signal clusters and a ratio of gene/chromosome per cell Ն2, or Ն15 copies of the genes per cell in Ն10% of analyzed cells). 8, 9 
EGFR FISH on Paraffin Sections
Formalin-fixed, paraffin-embedded tissue sections were cut into 4-m-thick sections that were incubated overnight at 56°C. Deparaffinization, pretreatment, enzyme digestion, and fixation of slides were performed using the Vysis paraffin pretreatment kit (Vysis) according to the manufacturer's recommended protocol. Denaturation and hybridization were performed in a HY-Brite denaturation/hybridization system for FISH (Vysis). LSI EGFR Spectrum Orange/CEP 7 Spectrum Green probe (Vysis) was applied to tissue sections that were denatured at 72°C for 2 minutes and hybridized overnight at 37°C. The slides were then washed in wash buffer at 72°C for 2 minutes and counterstained with DAPI. Control slides (Vysis) were included in each assay run. For each specimen, at least 100 cells were scored for both EGFR and chromosome 7 signals by image analysis. FISH images were processed at a magnification of ϫ1250 utilizing an Olympus MX60 fluorescence microscope with a 100 W mercury lamp. Separate narrow band pass filters were used for the detection of Spectrum Orange, Spectrum Green, and DAPI. Samples were defined as EGFR positive or negative according to the same criteria applied on cytologic samples. 8, 9 
Statistical Analysis
McNemar test was used to compare the EGFR FISH status between primary tumors and related metastatic sites. Differences were considered statistically significant when the p value was 0.05 or less. All statistical tests were two-sided.
RESULTS
The characteristics of the 31 NSCLC patients are described in Table 1 . The median age of the patients at diagnosis was 65 years old (with a range of 44 -80 years). There were 19 men and 12 women. Five patients (16%) had squamous cell carcinoma, 14 patients (45%) had ADK, and 12 (39%) had NSCLC not otherwise specified.
The thirty-one analyzed metastases (see above) were synchronous in 17 cases (55%) and metachronous in 14 cases (45%). In the metachronous metastases, the median interval between resection of the primary tumor and FNAB from the metastatic site was 19.5 months. None of the patients received prior EGFR targeted therapy; all patients were submitted to first-line chemotherapy treatment (after FNA in metastatic site).
EGFR FISH was assessable on 28 of the 31 archival histologic sections from primary NSCLC and on 28 of the 31 cytologic samples from the corresponding metastatic sites (10 cytologic smears were originally unstained, whereas 21 were destained from previous MGG staining). The feasibility of EGFR FISH on both cytology and histology was 90% (28 of 31 patients): three samples were not assessable both on cytology and histology because of lack of hybridization.
EGFR results obtained by FISH in the 28 assessable primary NSCLC and the corresponding distant metastatic lesions are shown in Table 2 . EGFR FISH was positive in 36% (10 of 28 patients) of the primary tumors and in 61% (17 of 28 patients) of the metastatic sites. Among 10 cases of EGFR FISH positive in the primary tumor, only two were amplified.
Nine of the 28 cases (32%) were EGFR FISH positive on both primary tumor and metastatic site and 10 (36%) were negative on both primary tumor and metastasis (Table 3 ). The two cases with EGFR gene amplification on primary tumor showed only polisomy on the corresponding metastatic site.
Nine of the 28 cases (32%) showed primary tumor versus metastasis discordance (McNemar test; p ϭ 0.041): in eight cases EGFR FISH was positive in the metastatic site but not in the primary tumor, whereas one sample was EGFR positive in the primary tumor but not in the metastasis.
EGFR FISH status in primary tumor and in the corresponding synchronous or metachronous metastases is shown Table 4 . No significant correlation was found, probably because of the small simple size. Five patients, after chemotherapy, received EGFR TKI therapy (three gefitinib and two erlotinib, respectively). Two patients demonstrated partial response and one stable disease during gefitinib treatment, whereas two evidenced progressive disease to erlotinib. About EGFR FISH in primary tumor versus metastasis, four of these five cases were concordant (two partial response and two progressive disease) and one, the patient with stable disease, discordant (EGFR positive in the primary tumor and negative in the metastasis; case number 19 of Table 2 ).
DISCUSSION
EGFR gene copy number is usually assessed by FISH technique and it is generally performed only on primary tumors, because recurrences are rarely neither removed nor undergone biopsy. Consequently, data referring to EGFR status in distant metastases are very limited.
The issue of EGFR expression consistency along the metastatic process in NSCLC is still not solved. We could assume that EGFR positivity of primary tumors incompletely predicts the response to EGFR TKIs, because of a change of EGFR status during metastatic progression. To select patients who will achieve the maximum benefit from EGFR inhibitors, it would be worth to ascertain the EGFR status in metastatic lesions in comparison with the corresponding primary tumors, considering that in advanced NSCLC the main targets of any therapy are the metastases.
Our data suggest that EGFR status does not remain stable during the metastatic progression. In fact, the correlation between EGFR FISH status in primary NSCLC cancer and in the corresponding metastatic sites is relatively poor. Nine of the 28 cases (32%) showed discordance of primary tumor versus metastasis; in particular, the majority of cases (eight of nine) were EGFR FISH positive in the metastasis but not in the primary tumor.
Up to now, only one other report has compared EGFR status in primary NSCLC with paired distant metastases, showing that EGFR expression is not stable during metastatic progression in a significant proportion of NSCLC. 10 In this study carried on 30 patients, EGFR status has been analyzed by IHC and FISH either on tumor samples of primary NSCLC or on biopsy samples obtained from one distant metastatic site at least. Thirty-three percentage of the cases showed primary tumor versus metastasis discordance by IHC analysis and 27% by FISH.
This discordance also has been observed by Petersen et al. who identified chromosomal imbalances of the 7p11 region, where the EGFR gene is mapped, by comparative genomic hybridization in a series of paired primary tumor and metastases of NSCLC. 11 Moreover, recently Park et al. found 6 of 11 advanced NSCLC patients (54.5%) showing discordance of EGFR mutation in the primary tumor versus metastasis site. 12 The lack of correlation of EGFR status between primary and metastatic sites, determined by IHC, was also demonstrated in colorectal cancer. 13 Our finding that EGFR status may be discrepant between primary NSCLC and the corresponding distant metastatic sites is novel and contributes to the debate about the best method for predicting response of NSCLC tumors to EGFR-targeted therapies. A switch from EGFR-negative status in the primary tumor to positive in the metastatic site was observed either in synchronous and in metachronous metastases; however, the number of cases was too small to draw any conclusion.
Moreover, it is necessary to consider chemotherapy treatment that occur before the EGFR TKI therapy and that could influence the EGFR status of metastatic disease. A switch from EGFR IHC-negative status to positive in four of six NSCLC patients undergone to preoperative chemotherapy was reported. 14 Based on EGFR mRNA expression, further investigations suggest that some NSCLC (25%) EGFR-positive circulating tumor cells might convert to a negative status on chemotherapy. 15 In light of this observation, assuming that EGFR status plays a role in prediction of TKI response, future trials should consider, whenever feasible, a rebiopsy immediately before starting gefitinib or erlotinib therapy. In our opinion, testing EGFR status exclusively on primary NSCLC specimens may be inadequate for planning an EGFR inhibitor therapy in metastatic disease. Based on our data by FNAB, performed on a NSCLC metastatic lesion, might represent an excellent provider of fresh cytologic material for an updated characterization of relevant predictive factors and a real-time EGFR assessment for EGFR inhibitor-based therapy.
To our knowledge, none of the studies that evaluated EGFR gene copy number by FISH on metastases from NSCLC patients has been performed on cytologic material. In our experience, FNAB guided by simple palpation for superficial lesions and by ultrasound for visceral metastasis is a relatively easy and safe method to obtain cellular material for FISH analysis. 7 This procedure has been proved to circumvent many methodologic limitations or interferences encountered on histologic material from primary NSCLC either by IHC or FISH, particularly when applied on archival samples. Previous studies have indicated that, in terms of feasibility and accuracy, FISH provides a tempting alternative to immunocytochemistry, whose specificity and sensitivity problems have been described. 16, 17 Conversely, in archival histologic specimens, later assessed by FISH, hybridization may be eventually compromised by Bouin fixation.
In conclusion, since the advent of EGFR inhibitors, the characterization of the molecular profile in metastatic disease has become increasingly important for targeted therapy selection. The results of the current study indicate the feasibility, the reliability, and the advantages of two relatively rapid and informative techniques, such as FNA and FISH, performed for ascertaining the malignant nature of a suspicious lesion and determining predictive markers for response to EGFR TKI therapy.
